Genmab (GMAB) submits Form 6-K incorporating Articles of Association

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Genmab A/S has furnished a Form 6-K for March 2026, primarily to submit its updated Articles of Association as Exhibit 3.1. The filing states that this report will be incorporated by reference into several existing Genmab Form S-8 registration statements and will form part of those documents from the filing date.

Form 6-K: How Foreign Companies Report to the SEC →

03/04/2026 - 11:32 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF MARCH 2026

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX



Exhibit			Description of Exhibit

3.1			Articles of Association

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



			GENMAB A/S

			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: MARCH 4, 2026

Source: View Original Filing on SEC EDGAR

FAQ

What did Genmab A/S (GMAB) file in its March 2026 Form 6-K?

Genmab A/S filed a Form 6-K furnishing its Articles of Association as Exhibit 3.1. The report is an informational submission by a foreign private issuer under the Securities Exchange Act of 1934.

How is Genmab A/S’s March 2026 Form 6-K used in its Form S-8 registrations?

The March 2026 Form 6-K is incorporated by reference into Genmab’s Form S-8 registration statements. This means the information in the 6-K legally becomes part of those S-8 filings from the date it is filed.

Which exhibit is included in Genmab A/S’s March 2026 Form 6-K?

The Form 6-K includes Exhibit 3.1, described as Genmab A/S’s Articles of Association. This exhibit provides the company’s foundational corporate governance document as part of its U.S. disclosure package.

Who signed Genmab A/S’s March 2026 Form 6-K filing?

The Form 6-K was signed on behalf of Genmab A/S by Anthony Pagano. He is identified in the filing as Executive Vice President & Chief Financial Officer of the company.

When was Genmab A/S’s March 2026 Form 6-K dated?

The Form 6-K is dated March 4, 2026. This date marks when the report, including the Articles of Association as Exhibit 3.1, was executed for submission under the Securities Exchange Act of 1934.

What type of issuer is Genmab A/S in this Form 6-K?

Genmab A/S is identified as a foreign private issuer filing a Form 6-K. This status allows the company to report certain information to U.S. investors under rules 13a-16 or 15d-16 of the Securities Exchange Act.

Filing Exhibits & Attachments

1 document